NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Evozyne

Evozyne

Private
Chicago, IllinoisHealthcare & Life Scienceshttps://evozyne.com/

Last Round

Series B

Sep 27, 2023

Total Funding Raised

$149.18M

Company Overview

Evozyne is a biotechnology company that operates a data-driven molecular engineering platform to develop innovative proteins with enhanced functionalities tailored to meet specific health challenges.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

protein designgenerative biologydrug discoveryprotein engineeringcomputational protein engineeringbiotechnologyin silico drug designindustrial enzyme engineeringAI drug discoveryprotein LLMbiocatalystsdeep learningtherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Evozyne Comparables

Compare Evozyne with similar companies based on industry and business-model similarity.

Evozyne comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nabla
88%
AI Proteins
86%
Profluent Bio
85%

Evozyne Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 27, 2023
Series AApr 21, 2021
SeedApr 27, 2020

Key People

Founding team and executive leadership

Marc Yoskowitz

Chief Executive Officer

Executive Team

Mike Gamson

Vice Chairman Of The Board, Former CEO

Executive Team

Arjun Rallapalli

Chief Operating Officer

Executive Team

Evozyne Investors

Notable investors and investment history

Evozyne investors
InvestorRounds
Fidelity Management & Research CompanySeries A, Series B
OrbiMedSeries B
Paragon BiosciencesSeed, Series B, Series A
NVenturesSeries B
Valor Equity PartnersSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 27, 2023

    $81M round led by Fidelity Management & Research Company and OrbiMed.

  • Apr 21, 2021

    $54M round with participation from Fidelity and Valor.

Evozyne Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Evozyne Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Evozyne's valuation, stock price, and market status.

Firmographic Details

HeadquartersChicago, Illinois
Employee Range54
Year Founded2019
Last FundingSep 27, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.